Analysis
Cardiac Biotech Joins August's IPO Rush
Braveheart Bio priced its IPO at $16 a share, the midpoint of its $15-to-$17 range, selling 18.75 million shares to raise $300 million on Nasdaq, according to IPOScoop. The company's lead candidate, BHB-1893, is a pill being evaluated to treat hypertrophic cardiomyopathy, a thickening of the heart muscle that can cause sudden cardiac events and currently has a limited set of approved treatments.
“Cardiovascular drug developers Cytokinetics and Bristol Myers Squibb's mavacamten franchise are the closest public comparables for BHB-1893's target indication.”
Braveheart's pricing lands in the same week as Attovia Therapeutics' $289 million IPO and Vogenx's roughly $68 million offering, making early August the busiest stretch for biotech listings so far this year, per PharmExec. All three priced within days of each other, which is either a sign the biotech window has genuinely reopened or evidence issuers are racing to get out before conditions change -- both readings are consistent with the same data.
The comparable to watch is Apnimed, which priced at $16 on July 31 and returned 56% on its first trading day -- a print strong enough that bankers have reportedly used it to pull forward other biotech issuers' timelines, Braveheart's among them. Cardiovascular drug developers Cytokinetics and Bristol Myers Squibb's mavacamten franchise are the closest public comparables for BHB-1893's target indication.
The caveat worth noting: a $300 million raise funds clinical development, not commercial launch, and hypertrophic cardiomyopathy already has an approved mavacamten-class treatment on the market, meaning Braveheart's drug has to differentiate on safety or efficacy against a real competitor, not an open field. What to watch: Braveheart's first-week trading performance relative to Attovia's, which will tell bankers whether the current biotech window can support more than one listing at a time.